Video

Dr. Abramson on Safety and Efficacy of Liso-Cel in Relapsed/Refractory Large B-Cell Lymphoma

Author(s):

Jeremy Abramson, MD
Conference|ASH Annual Meeting and Exposition

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the pivotal safety and efficacy results from phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory large B-cell lymphoma.

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the pivotal safety and efficacy results from phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory large B-cell lymphoma.

<<< View more from the 2019 ASH Annual Meeting

Related Videos
Sumanta Kumar Pal, MD, FASCO,
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
James Ignatz-Hoover, MD, PhD
Sundar Jagannath, MBBS
Krina K. Patel, MD, MSc
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center
Related Content
Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
October 10th 2022

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Benjamin J. Solomon, MBBS, PhD
May 31st 2024

Lorlatinib Yields Longest Reported PFS in Advanced NSCLC

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL
July 28th 2022

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

FDA
May 30th 2024

FDA Approves Liso-Cel for R/R Mantle Cell Lymphoma After 2 Lines of Therapy

Pancreatic Cancer
May 29th 2024

CT041 Shows Tolerability and Early Efficacy in Refractory Metastatic Pancreatic Cancer